| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 10/05/2004 | US6800291 Uro-genital condition treatment system |
| 10/05/2004 | US6800290 Variants can be used in specific immunotherapy of allergic pathologies caused by dust mites |
| 10/05/2004 | US6800287 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| 10/05/2004 | US6800286 Chimeric fibroblast growth factor proteins, nucleic acid molecules, and uses thereof |
| 10/05/2004 | US6800285 Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| 10/05/2004 | US6800284 Atp diphosphohydrolase for use in the treatment of pancreatic and heart disorders |
| 10/05/2004 | US6800280 Administering human granulocyte-macrophage stimulating factor (gm-csf) to induce a clinically significant increase in the patient's cd4+ t- lymphocyte count |
| 10/05/2004 | CA2264243C Glp-1 derivatives |
| 10/05/2004 | CA2128833C P53as protein and antibody therefor |
| 10/04/2004 | CA2463115A1 Anti-inflammatory composition |
| 10/01/2004 | CA2423876A1 Novel selective bradykinin (bk) b1 peptidic receptor antagonists and uses thereof |
| 09/30/2004 | WO2004083861A1 Compounds and methods for detecting tripeptidyl protease i |
| 09/30/2004 | WO2004083446A2 Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| 09/30/2004 | WO2004083435A1 Nab proteins and their use in diagnostic and therapeutic applications in heart disease |
| 09/30/2004 | WO2004083434A1 A combined adeno-associated virus and adenovirus cocktail gene delivery system for high effiency gene expression without eliciting immune response in immuno-competent subjects |
| 09/30/2004 | WO2004083433A1 Sirna expression cassette and research tool kit comprising it |
| 09/30/2004 | WO2004083432A1 Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
| 09/30/2004 | WO2004083430A2 SHORT INTERFERING RNA (siRNA) ANALOGUES |
| 09/30/2004 | WO2004083421A1 Method for the production of gla-residue containing serine proteases |
| 09/30/2004 | WO2004083404A2 Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain |
| 09/30/2004 | WO2004083398A2 Therapeutic uses of hmgn1 and hmgn2 |
| 09/30/2004 | WO2004083396A2 Methods for the identification of inhibitors of porphobilinogen deaminase, bifunctional purine biosynthetic protein, and a transcription factor as antibiotics |
| 09/30/2004 | WO2004083388A2 Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74 |
| 09/30/2004 | WO2004083383A2 Globin variant gene methods and compositions |
| 09/30/2004 | WO2004083382A2 Compositions and methods for treating hyperimmune response in the eye |
| 09/30/2004 | WO2004083381A2 Fibroblast growth factor receptor-1 polynucleotides, polypeptides, and mutants |
| 09/30/2004 | WO2004083376A2 Modulators |
| 09/30/2004 | WO2004083375A2 Methods of promoting the differentiation of stem cells |
| 09/30/2004 | WO2004083365A2 Compounds and their use for specific and simultaneous inhibition of genes involved in diseases and related drugs |
| 09/30/2004 | WO2004083361A2 FVII OR FVIIa VARIANTS |
| 09/30/2004 | WO2004083258A2 Branched water-soluble polymers and their conjugates |
| 09/30/2004 | WO2004083245A2 Agent comprise an albumin-like first polypeptide bound to a second polypeptide |
| 09/30/2004 | WO2004083244A2 Specific inhibition of allograft rejection |
| 09/30/2004 | WO2004083243A1 Amylin aggregation inhibitors and use thereof. |
| 09/30/2004 | WO2004083241A2 Btc-interacting proteins and use thereof |
| 09/30/2004 | WO2004083240A2 Regulation of gene expression |
| 09/30/2004 | WO2004083239A1 Determining drug resistance |
| 09/30/2004 | WO2004083236A2 Cancer treatment using proanp peptides |
| 09/30/2004 | WO2004083234A2 Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| 09/30/2004 | WO2004083231A2 Use of peptide ligands for plasma membrane receptors or similar for mitochondrial activity modulation |
| 09/30/2004 | WO2004083186A1 Therapeutic agent for viral hepatitis and carcinostatic agent |
| 09/30/2004 | WO2004082744A1 Method and system for colloid exchange therapy |
| 09/30/2004 | WO2004082720A1 Drug for treating hemophilia and method of treating hemophilia using the same |
| 09/30/2004 | WO2004082715A1 Concomitant drug as therapeutic agent for inflammatory bowel disease |
| 09/30/2004 | WO2004082709A1 Angiotensin-converting enzyme inhibitory peptides |
| 09/30/2004 | WO2004082708A2 Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides |
| 09/30/2004 | WO2004082707A2 Stabilisation of growth hormones in solution |
| 09/30/2004 | WO2004082706A2 Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders |
| 09/30/2004 | WO2004082705A1 Treatment of dupuytren’s contracture |
| 09/30/2004 | WO2004082704A1 Method of treating inflammtory disease associated with bone destruction |
| 09/30/2004 | WO2004082703A1 Combined use of g-csf with angiogenetic factor |
| 09/30/2004 | WO2004082702A1 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy |
| 09/30/2004 | WO2004082701A1 New engineered antibiotic peptide and its preparing process |
| 09/30/2004 | WO2004082640A2 Human serum albumin conjugates with therapeutic compounds |
| 09/30/2004 | WO2004082634A2 Facially amphiphilic polymers and oligomers and uses thereof |
| 09/30/2004 | WO2004082629A2 Novel cyclosporins |
| 09/30/2004 | WO2004082608A2 Ligands for tgf-beta binding proteins and uses thereof |
| 09/30/2004 | WO2004082602A2 Carboxamide spirohydantoin cgrp receptor antagonists |
| 09/30/2004 | WO2004082599A2 Combination of an aldosterone receptor antagonist and an anti-diabetic agent |
| 09/30/2004 | WO2004082595A2 Therapeutic use of tumor necrosis factor-alpha mutein |
| 09/30/2004 | WO2004082578A2 Use of soluble cd14 for treatment of diseases |
| 09/30/2004 | WO2004082573A2 Diagnostics and therapeutics for diseases associated with dopamine receptor d4 (drd4) |
| 09/30/2004 | WO2004082569A2 Diagnostics and therapeutics for diseases associated with dopamine receptor d3 (drd3) |
| 09/30/2004 | WO2004082568A2 Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar) |
| 09/30/2004 | WO2004082459A2 Methods of administering a material into a patient for dermal enhancement |
| 09/30/2004 | WO2004069266A3 Use of bradykinin-b2 receptor antagonists for treating osteoarthrosis |
| 09/30/2004 | WO2004064785A9 Cancer therapy sensitizer |
| 09/30/2004 | WO2004060408A8 p53 TREATMENT OF PAPILLOMAVIRUS AND CARCINOGEN-TRANSFORMED CELLS IN HYPERPLASTIC LESIONS |
| 09/30/2004 | WO2004056861A3 Glycoisoforms of adiponectin and uses thereof |
| 09/30/2004 | WO2004053083A3 Modulation of fetoprotein transcription factor expression |
| 09/30/2004 | WO2004052920A3 Conversion of apoptotic proteins |
| 09/30/2004 | WO2004052917A9 Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions |
| 09/30/2004 | WO2004052308A3 Topical anti-infective formulations |
| 09/30/2004 | WO2004050689A3 Aza-peptides |
| 09/30/2004 | WO2004046355A3 Protein specific to pancreatic beta cells in islets of langerhans and applications thereof |
| 09/30/2004 | WO2004045544A3 Autocrine growth factor receptor antibodies and methods |
| 09/30/2004 | WO2004044004A3 T cell receptor display |
| 09/30/2004 | WO2004039957A3 Inhibition of gene expression using rna interfering agents |
| 09/30/2004 | WO2004038405A3 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43) |
| 09/30/2004 | WO2004037164A3 Crosslinked compounds and methods of making and using thereof |
| 09/30/2004 | WO2004034813A3 Composition for reducing caloric intake |
| 09/30/2004 | WO2004032849A3 Methods of administering fgf18 |
| 09/30/2004 | WO2004032716A3 Compounds for modulation of cholesterol transport |
| 09/30/2004 | WO2004031411A3 Genes and polypeptides relating to human pancreatic cancers |
| 09/30/2004 | WO2004030519A3 Thymic atrophy |
| 09/30/2004 | WO2004022059A3 Use of 6 amino-quinoline-5, 8 quinones and nucleic acids associated with senescence for the treatment of tumors |
| 09/30/2004 | WO2004011613A3 Composition & methods for treatment and screening |
| 09/30/2004 | WO2004011610A3 Antisense modulation of polo-like kinase expression |
| 09/30/2004 | WO2003106629A3 Treating vitamin d responsive diseases |
| 09/30/2004 | WO2003102014A3 Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
| 09/30/2004 | WO2003082200A3 Potent oncolytic herpes simplex virus for cancer therapy |
| 09/30/2004 | WO2003080105A9 Angiogenesis regulator genes, pharmaceutical preparations containing same and uses thereof |
| 09/30/2004 | WO2003073097A3 Methods for isolating ligands e.g. t cell epitopes |
| 09/30/2004 | WO2003072740A3 Novel type-1 cytokine receptor glm-r |
| 09/30/2004 | WO2003072593A3 Bone targeting peptides |
| 09/30/2004 | WO2003062447A3 Nuclear-envelope and nuclear-lamina binding chimeras for modulating gene expression |
| 09/30/2004 | WO2003052065A3 Antisense modulation of b-cell associated protein expression |
| 09/30/2004 | WO2003049703A3 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof |
| 09/30/2004 | WO2003048328A9 Antibodies against carboxic anhydrase ix (ca ix) tumor antigen |
| 09/30/2004 | WO2003039491A3 Novel isoforms of vascular endothelial cell growth inhibitor |